STUDY SCHEMA



4.0 PARTICIPANT ELIGIBILITY

4.1 Inclusion Criteria

Participants must:

4.1.1 Be diagnosed with Stage I-IV prostate cancer without metastases to bone (lymph node involvement and prior diagnosis of a primary cancer is allowed).

4.1.2 Be age 60 years or older.

4.1.3 Be starting ADT or have received their first ADT treatment in the past 3 months, with at least 6 planned months of treatment remaining (both luteinizing hormone-releasing hormone (LHRH) antagonists and LHRH agonists are permitted).

4.1.4 Have a total serum vitamin D between 10 and 27 ng/ml.

4.1.5 Have a total serum calcium of less than or equal to 10.5 mg/dl.

4.1.6 Have a normal GFR (glomerular filtration rate)

4.1.7 Agree not to take calcium and/or vitamin D supplements for the duration of the intervention other than those provided by the study.

4.1.8 Be able to provide written informed consent.

4.1.9 Be able to swallow pills and capsules.

4.1.10 Be able to speak and read English.

4.2 Exclusion Criteria

Participants must NOT:

4.2.1 Have long term (greater than 3 months) use of any pharmacologic bone-modifying agent including but not limited to oral or IV bisphosphonates, denosumab, or teriparatide prior to enrollment.

4.2.2 Have a diagnosis of stage IV chronic kidney disease.

4.2.3 Have a diagnosis of grade II or greater hypercalcemia (serum calcium greater than 10.5 mg/dl)

4.2.4 Have a history of hypercalcemia or vitamin D toxicity/sensitivity.